Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Intranet
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

Pfizer’s Adalimumab Biosimilar PBS-listed in Australia

Aug 1, 2024

On 1 August 2024, the PBS published its Summary of Changes, which included listing Pfizer’s Abrilada®, biosimilar to AbbVie’s Humira® (adalimumab), on the PBS in 20mg/0.4mL and 40mg/0.8mL dosage injections.

This comes three years after Abrilada was first recommended or listing in July 2021 by Australia’s Pharmaceutical Benefits Advisory Council; required documentation was not submitted by Pfizer until February this year.  Abrilada was first approved by the TGA in March 2021, being indicated for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, as well as Crohn’s disease, ulcerative colitis, psoriasis, hidradenitis suppurativa and uveitis.